Blueprint Medicines Expands Precision Therapy With Lengo Therapeutics Acquisition


Blueprint Medicines Corporation BPMC has agreed to acquire Lengo Therapeutics, a privately held precision oncology company.

  • The deal consideration includes $250 million in cash plus $215 million in additional potential milestone payments.
  • The acquisition includes Lengo Therapeutics' lead compound LNG-451, a precision therapy in development to treat non-small cell lung cancer in patients with EGFR exon 20 insertion mutations. 
  • Lengo Therapeutics anticipates submitting an investigational new drug application for LNG-451 to the FDA in December 2021.
  • Blueprint Medicines anticipates the acquisition will close in Q4 of 2021.
  • Related Link: Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates.
  • Price Action: BPMC shares are down 2.16% at $98.67 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechM&ANewsHealth CareMoversTrading IdeasGeneralBriefsNon-Small Cell Lung Cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!